New Coating for Urinary Intermittent Catheters

NCT ID: NCT06985888

Last Updated: 2025-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-06

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal is to confirm, that the newly developed coating is non-inferior to the comparator with respect to the overall discomfort of the catheterisation (assessed by participant).

Participants will attend 3 study site visits and will be catheterised by a HCP at visit 1 and 2 with one of the two catheters in randomisation order. Urine samples will be collected pre- and post catheterisation for assessments.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of the study is to confirm that the newly developed investigational coating is non-inferior to the comparator coating with respect to the overall discomfort of catheterisation.

The investigational device is a ready-to-use, sterile, hydrophilic-coated Nelaton male catheter for intermittent catheterisation and based on the standard SpeediCath® male intermittent catheter with a difference in the composition on the coating.

The study is a double-blinded, randomized, crossover study including 32 randomized healthy male volunteers. The total study duration for the individual subject will be between 4-21 days and consists of 3 site visits V0, V1 and V2, and V0 andV1 can be combined

At V1 and V2 the subjects will be catheterized in a hospital setting by a health care professional, with one of the two catheters in a randomized order. Subject will be asked to assess the overall discomfort of the catheterisation on VAS.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retention, Urinary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Catheterisation with investigational device and Comparator

Group Type OTHER

SpeediCath® Standard male new coating

Intervention Type DEVICE

Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male new coating CH12 by HCP

SpeediCath® Standard male

Intervention Type DEVICE

Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male CH 12 by HCP

Catheterisation with Comparator and Investigational device

Group Type OTHER

SpeediCath® Standard male new coating

Intervention Type DEVICE

Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male new coating CH12 by HCP

SpeediCath® Standard male

Intervention Type DEVICE

Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male CH 12 by HCP

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SpeediCath® Standard male new coating

Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male new coating CH12 by HCP

Intervention Type DEVICE

SpeediCath® Standard male

Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male CH 12 by HCP

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Has given written informed consent
2. Is at least 18 years old
3. Has full legal capacity
4. Has self-assessed intact male anatomy with no abnormalities or disease of the lower urinary tract or any surgical procedures performed in the lower urinary tract
5. Is able (assessed by investigator) and willing to adhere to study procedures during study duration.
6. Is able to refrain from using analgesics up to 24 hours prior to catheterisation visits
7. Is negative for haematuria, measured by urine dipstick test of erythrocytes

Exclusion Criteria

1. Is participating in any other clinical investigation during this investigation, which could affect the results of this investigation, as assessed by investigator.
2. Has previously been randomized in this investigation.
3. Has known hypersensitivity towards any of the devices used in the investigation
4. Is currently experiencing symptoms associated with UTI, as assessed by investigator.
5. Has known impaired sensation of the urethra
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Coloplast A/S

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Urology, Rigshospitalet

Copenhagen, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CP372

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Feasibility Assessment of ACS Catheter
NCT01960517 WITHDRAWN PHASE2/PHASE3